Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
73.68 USD | +0.57% | -1.40% | +2.62% |
Business Summary
Number of employees: 610
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Small Molecule Drugs
100.0
%
| 250 | 100.0 % | 464 | 100.0 % | +85.51% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 250 | 100.0 % | 464 | 100.0 % | +85.51% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sharon Mates
CEO | Chief Executive Officer | 71 | 28/08/13 |
Director of Finance/CFO | 67 | 28/08/13 | |
Michael Halstead
PSD | President | 51 | 30/06/14 |
Willie Earley
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/22 |
Suresh Durgam
CTO | Chief Tech/Sci/R&D Officer | - | - |
Karen Sheehy
CMP | Compliance Officer | 62 | 01/07/19 |
Robert Davis
CTO | Chief Tech/Sci/R&D Officer | 73 | 31/10/15 |
Juan F. Sanchez
IRC | Investor Relations Contact | - | 09/03/14 |
John A. Bardi
LAW | General Counsel | - | 25/03/19 |
General Counsel | - | 31/08/18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
BRD | Director/Board Member | 71 | 07/01/14 |
Joel Marcus
BRD | Director/Board Member | 76 | 28/08/13 |
Director/Board Member | 67 | 07/01/14 | |
Sharon Mates
CEO | Chief Executive Officer | 71 | 28/08/13 |
Rene Salas
BRD | Director/Board Member | 62 | 19/04/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 104,256,524 | 101,717,520 ( 97.56 %) | 0 | 97.56 % |
Company contact information
Intra-Cellular Therapies, Inc.
430 East 29th Street Suite 900
10016, New York
+646 440 9333
http://www.intracellulartherapies.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.62% | 7.72B | |
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-13.74% | 15.36B | |
-8.82% | 11.95B | |
-15.66% | 11.6B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B |
- Stock Market
- Equities
- ITCI Stock
- Company Intra-Cellular Therapies, Inc.